mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
Nature Medicine·
- DOI
- 10.1038/s41591-021-01446-y
- PMID
- 34244681
- PMCID
- —
- OpenAlex
- —
- Study type
- Case-control study
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The findings demonstrate high vaccine effectiveness against variants of concern and severe outcomes, supporting vaccination efforts during periods of variant circulation.
Structured evidence summary
Research question
The study assessed real-world effectiveness of the mRNA-1273 vaccine against SARS-CoV-2 variants B.1.1.7 and B.1.351, as well as severe COVID-19 outcomes, in Qatar.
Study design
A matched test-negative, case-control study design was used to evaluate vaccine effectiveness in a real-world setting.
Population and setting
The study was conducted in Qatar, where the population comprises mainly working-age adults.
Main findings
Vaccine effectiveness against B.1.1.7 was 88.1% after the first dose and 100% after the second dose. Against B.1.351, effectiveness was 61.3% after the first dose and 96.4% after the second dose. Effectiveness against severe, critical, or fatal disease was 81.6% after the first dose and 95.7% after the second dose.
Public-health relevance
The findings demonstrate high vaccine effectiveness against variants of concern and severe outcomes, supporting vaccination efforts during periods of variant circulation.
Important limitations
This summary relies on the supplied single-article abstract and metadata. Full interpretation of study limitations, including potential confounding, selection bias, and generalizability beyond a predominantly working-age population, requires review of the complete published paper.
GIDS interpretation
The article addresses vaccine effectiveness and was classified under vaccination and treatment topics for Qatar, making it discoverable in searches related to COVID-19 vaccine performance against specific variants.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 12 auditable classifier relationships to diseases, places, topics, and study design.